The success of Sildenafil initially drove a surge for pharma, but recent shifts present a murky outlook for those considering a stake. Generic versions are reducing earnings, and continued patent challenges add https://karimeext133786.bloggerbags.com/46897529/sildenafil-and-big-pharma-a-risky-investment